Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant interleukin-2: a biological response modifier.

P E Kintzel1, K A Calis

  • 1Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX.

Clinical Pharmacy
|February 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of metformin on energy intake and satiety in obese children.

Diabetes, obesity & metabolism·2014
Same author

A clinical research integration special program (CRISP) for young women with primary ovarian insufficiency.

Panminerva medica·2014
Same author

Prophylaxis for paclitaxel hypersensitivity reactions.

The Annals of pharmacotherapy·2001
Same author

Use of a parenteral propylene glycol-containing etomidate preparation for the long-term management of ectopic Cushing's syndrome.

The Journal of clinical endocrinology and metabolism·2001
Same author

Safety reporting in clinical trials.

JAMA·2001
Same author

Hydrocortisone suspension and hydrocortisone tablets are not bioequivalent in the treatment of children with congenital adrenal hyperplasia.

The Journal of clinical endocrinology and metabolism·2001
Same journal

Criteria for use of epoetin alfa in adult cancer and orthopedic-surgery patients.

Clinical pharmacy·1993
Same journal

Accuracy of unbound-quinidine concentration determination after ultrafiltration.

Clinical pharmacy·1993
Same journal

Modified Michaelis-Menten equation for estimating unbound-phenytoin concentrations.

Clinical pharmacy·1993
Same journal

Predicting vancomycin pharmacokinetics by using aminoglycoside pharmacokinetics.

Clinical pharmacy·1993
Same journal

Efficacy of nutritional supplements used by athletes.

Clinical pharmacy·1993
Same journal

Low-molecular-weight heparins for the treatment of deep-vein thrombosis.

Clinical pharmacy·1993
See all related articles

Recombinant interleukin-2 (IL-2) is an immunomodulating agent showing promise in treating renal cell cancer and melanoma. While effective, its severe, dose-related side effects necessitate administration in a critical-care setting.

Area of Science:

  • Immunology
  • Pharmacology
  • Oncology

Background:

  • Recombinant interleukin-2 (IL-2) is an immunomodulating agent.
  • It stimulates key immune cells like T cells, B cells, natural killer cells, and thymocytes.
  • Aldesleukin and teceleukin are two extensively studied IL-2 products.

Purpose of the Study:

  • To review the properties, clinical applications, and safety of recombinant IL-2.
  • To assess its efficacy in treating specific cancers.
  • To understand its administration, adverse effects, and optimal use.

Main Methods:

  • Review of chemical properties, pharmacology, immunology, pharmacokinetics, and clinical trials.
  • Analysis of treatment protocols, including combination therapies and dosage adjustments.

Related Experiment Videos

  • Evaluation of adverse events and necessary supportive care measures.

    • Main Results:

    • Recombinant IL-2 has shown positive responses in patients with renal cell cancer and melanoma, cancers often resistant to conventional therapies.
    • It has been used alone or in combination with other agents like lymphokine-activated killer cells and interferons.
    • Adverse effects are typically reversible but can be severe and dose-dependent, including hypotension, edema, and renal dysfunction.

    Conclusions:

    • Recombinant IL-2 represents a significant advancement in treating renal cell cancer and melanoma.
    • Its use requires careful administration in a critical-care setting due to potential severe side effects.
    • It offers a novel therapeutic strategy for various refractory or recurrent malignancies.